DrugPatentWatch Database Preview
Drugs in Development Information for BRL-15,572
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug BRL-15,572?
BRL-15,572 is an investigational drug.
There have been 5 clinical trials for BRL-15,572.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2000.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Leishmaniasis. The leading clinical trial sponsors are GlaxoSmithKline, Directorate General of Health Services of Bangladesh, and National Taiwan University Hospital.
Summary for BRL-15,572
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2000-04-01) |
| Vendors | 6 |
Recent Clinical Trials for BRL-15,572
| Title | Sponsor | Phase |
|---|---|---|
| A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | Celgene | Phase 1/Phase 2 |
| A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | Mundipharma Research GmbH & Co KG | Phase 1/Phase 2 |
| A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | Roche Pharma AG | Phase 1/Phase 2 |
Clinical Trial Summary for BRL-15,572
Top disease conditions for BRL-15,572
Top clinical trial sponsors for BRL-15,572
US Patents for BRL-15,572
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
